Experimental treatments for sickle cell disease

Crovalimab is an antibody-based, add-on therapy being developed by Genentech to treat and prevent painful vaso-occlusive crises in people with SCD. It is being explored as an into-the-vein (intravenous) infusion followed by under-the-skin (subcutaneous) injections.

Etavopivat, formerly known as FT-4202, is an investigational oral small molecule being developed by Novo Nordisk to treat people with SCD. It is administered in the form of oral tablets to be taken by mouth.

Inclacumab is an investigational antibody-based therapy being developed by Pfizer to prevent painful vaso-occlusive crises in people with SCD. The therapy is administered via an into-the-vein (intravenous) infusion.

Memantine is a medication that’s approved to treat moderate to severe dementia in people with Alzheimer’s disease. It has also been explored as a possible treatment to help reduce red blood cell sickling in people with SCD. When used in SCD patients, memantine has been administered in the form of oral tablets.

Mitapivat is an experimental oral therapy being investigated as a possible treatment for SCD. The therapy, being developed by Agios Pharmaceuticals, is administered in the form of oral tablets to be taken by mouth.

Osivelotor is an investigational oral therapy being evaluated as a possible treatment for SCD. The therapy, currently being developed by Pfizer, is administered in the form of oral tablets to be taken by mouth.

Riociguat is a therapy that’s approved to treat some forms of pulmonary hypertension — disorders characterized by high blood pressure in certain blood vessels in the lungs. Although is not approved to treat SCD, riociguat has been used off-label in SCD patients to help manage high blood pressure and other complications. It is administered in the form of oral tablets.